Form NRC-374 (9-78)

U. S. NUCLEAR REGULATORY COMMISSION
MATERIALS LICENSE

Amendment No. 11

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter 1, Parts 30, 31, 32, 33, 34, 35, 36, 40 and 70, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s); and to import such byproduct and source material. This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

Licensee	In accordance with application dated December 11, 1978,
1. Delnor Hospital	3. License number 12-15842-01 is amended in its entirety to read as follows:
2. 975 North Fifth Avenue St. Charles, Illinois 60174	4. Expiration date August 31, 1984
	5. Docket or Reference No.

6. Byproduct, source, and/or special nuclear material	7. Chemical and/or physical form	8. Maximum amount that licensee may possess at any one time under this license
A. Any byproduct material listed in Groups I and II of Schedule A, Section 35.100 of 10 CFR 35	A. Any radiopharmaceutical listed in Groups I and II of Schedule A, Section 35.100 of 10 CFR 35	A. As necessary for uses authorized in Subitem 9.A.
B. Any byproduct material listed in Group III of Schedule A, Section 35.100 of 10 CFR 35	B. Any form listed in Group III of Schedule A, Section 35.100 of 10 CFR 35	B. 2 curies of each byproduct material authorized in Subitem 6.B.
C. Any byproduct material listed in Group IV of Schedule A, Section 35.100 of 10 CFR 35	C. Any radiopharmaceutical listed in Group IV of Schedule A, Section 35.100 of 10 CFR 35	C. As necessary for uses authorized in Subitem 9.C.
D. Iodine-131	D. Iodide	D. 250 millicuries
E. Xenon-133	E. Free gas or solution	E. 100 millicuries

ATTACHMENT #6

...AR REGULATORY COMMISSION

...NSE License Number 12-15842-01

Continued From Page 1

9. Authorized use

A. Any diagnostic procedure listed in Groups I and II of Schedule A, Section 35.100 of Title 10, Code of Federal Regulations.

B. Preparation and use of radiopharmaceuticals for any diagnostic procedure listed in Group III of Schedule A, Section 35.100 of Title 10, Code of Federal Regulations.

C. Any therapeutic procedure listed in Group IV of Schedule A, Section 35.100 of Title 10, Code of Federal Regulations.

D. Treatment of thyroid carcinoma.

E. Blood flow studies. Pulmonary function studies.

CONDITIONS

10. Licensed material shall be used only at the licensee's address stated in Item 2 above.

11. The licensee shall comply with the provisions of Title 10, Chapter 1, Code of Federal Regulations, Part 19, "Notices, Instructions and Reports to Workers; Inspections" and Part 20, "Standards for Protection Against Radiation."

12. Licensed material listed in Item 6 above is authorized for use by, or under the supervision of, the following individual(s) for the materials and uses indicated:

Alvin A. Zeman, M.D.	All
James C. Pritchard, M.D.	Groups I, II, III, and Xenon-133
Virginia N. Patterson, M.D.	All
Robert A. Carrara, M.D.	Groups I, II, III, and Xenon-133
Philip E. Rathbun, M.D.	Groups I, II, III, Xenon-133, Iodine-131 for treatment of hyperthyroidism and cardiac dysfunction, and soluble Phosphorus-32 for therapy
Nicholas C. Burriesci, M.D.	All

From Page 2

TIONS

For a period not to exceed sixty (60) days in any calendar year, a visiting physician is authorized to use licensed material for human use under the terms of this license, provided the visiting physician:

(a) Has the prior written permission of the hospital's Administrator and its Medical Isotopes Committee, and

(b) Is specifically named as a user on a Nuclear Regulatory Commission license authorizing human use, and

(c) Performs only those procedures for which he is specifically authorized by a Nuclear Regulatory Commission license.

The licensee shall maintain for inspection by the Commission copies of the written permission specified in subitem (a) above and of the license(s) specified in subitems (b) and (c) above. These records shall be maintained for five (5) years from the time the licensee grants its permission under subitem (a) above.

14. Licensed material shall be used in accordance with the provisions of Section 35.14(b)(c)(e) and (f) of Title 10, Code of Federal Regulations.

15. Patients containing Iodine-131 for the treatment of thyroid carcinoma or patients containing therapeutic quantities of Gold-198 shall remain hospitalized until the residual activity is 30 millicuries or less.

16. Radioactive gases as free gas or in solution, to be administered to humans, shall be procured from a supplier who distributes the product indicated for human use in accordance with the Federal Food, Drug, and Cosmetic Act.

17. Except as specifically provided otherwise by this license, the licensee shall possess and use licensed material described in Items 6, 7, and 8 of this license in accordance with statements, representations, and procedures contained in application dated December 11, 1978 and letter dated January 31, 1979.

Date EB 7 1979

For the U. S. Nuclear Regulatory Commission

John W. Cooper

by License Management Branch

Division of Fuel Cycle and
Material Safety
Washington, D.C. 20555

Medical Isotopes Committee Membership

Alvin A. Zeman- Chairman	Radiologist &Radiation Safety Officer
Robert Carrarra	Pathologist
J. Gagnon	Radiologist
G. Smoron	Radiologist
John Taft, Jr.	President -Institutions management
Rodney Nelson, III	Internal Medicine-M.D.

Attachment #7